Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Erasca, Inc. ERAS

Healthcare  —  Biotechnology
14.25 (0.27) (1.86%) as of 25 Sep
Market cap
$5.1B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Erasca, Inc. (ERAS) Business Profile

Updated before January 2025

Company Overview

Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage biotechnology company dedicated to eradicating cancer and advancing precision oncology. Founded in 2018 and headquartered in San Diego, California, Erasca focuses on developing innovative therapies targeting key oncogenic drivers. The company’s name, Erasca, is derived from its mission to “erase cancer.” The founding team includes industry veterans with extensive experience in oncology drug development, and the company is led by its CEO, Jonathan E. Lim, M.D., who has a strong track record in the biotech sector. Erasca has assembled a world-class leadership team and scientific advisory board, including prominent researchers and clinicians in the oncology field.

Core Business Segments

Erasca operates primarily in the biotechnology and pharmaceutical sectors, with a focus on oncology. The company’s core business segments include:

1. Small Molecule Inhibitors

Erasca is developing small molecule inhibitors targeting oncogenic drivers such as KRAS and other RAS/MAPK pathway components. These inhibitors are designed to block the signaling pathways that drive tumor growth and proliferation. Key products in this category include:

  • ERAS-007: A potent oral inhibitor targeting ERK1/2, a key node in the RAS/MAPK pathway.
  • ERAS-601: A SHP2 inhibitor designed to disrupt upstream signaling in the RAS/MAPK pathway.

2. Biologics and Combination Therapies

Erasca is also exploring biologics and combination therapies to enhance the efficacy of its small molecule inhibitors. These therapies aim to address resistance mechanisms and improve patient outcomes. Notable programs include:

  • ERAS-801: A CNS-penetrant EGFR inhibitor for glioblastoma and other brain cancers.
  • Combination regimens involving ERAS-007 and ERAS-601 to target multiple nodes in the RAS/MAPK pathway.

3. Precision Oncology Platforms

Erasca leverages cutting-edge technologies and partnerships to develop precision oncology platforms. These platforms integrate genomic data, biomarker-driven approaches, and advanced drug discovery techniques to identify and target oncogenic drivers more effectively.

Business Model

Erasca’s business model is centered on innovation, collaboration, and value creation. The company integrates its products and services through the following approaches:

  • Research and Development (R&D): Erasca invests heavily in R&D to discover and develop novel therapies targeting oncogenic drivers. The company collaborates with academic institutions, research organizations, and industry partners to accelerate drug development.
  • Clinical Trials: Erasca conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies. The company’s pipeline includes multiple programs in various stages of clinical development.
  • Partnerships and Licensing: Erasca forms strategic partnerships with other biotech and pharmaceutical companies to access complementary technologies and expand its product portfolio. Licensing agreements also provide additional revenue streams.
  • Revenue Generation: While Erasca is currently in the clinical-stage and does not yet generate significant revenue from product sales, the company plans to commercialize its therapies upon regulatory approval. Future revenue streams will include product sales, licensing fees, and milestone payments.

Strategic Direction

Erasca is committed to achieving its mission of erasing cancer through the following strategic initiatives:

  • Pipeline Expansion: The company aims to expand its pipeline by developing additional therapies targeting oncogenic drivers and resistance mechanisms. This includes exploring new targets within the RAS/MAPK pathway and beyond.
  • Global Reach: Erasca plans to establish a global presence by pursuing regulatory approvals in key markets such as the United States, Europe, and Asia.
  • Sustainability Goals: Erasca is dedicated to sustainability and ethical practices in its operations. The company prioritizes patient safety, environmental responsibility, and community engagement.
  • Innovation and Technology: Erasca continues to invest in cutting-edge technologies, such as artificial intelligence and machine learning, to enhance drug discovery and development processes.

Competitive Landscape

Erasca operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amgen, Inc.: A leader in oncology with a focus on KRAS inhibitors, including its FDA-approved drug Lumakras.
  • Mirati Therapeutics, Inc.: A clinical-stage biotech company developing KRAS inhibitors such as adagrasib.
  • Revolution Medicines, Inc.: Focused on targeting the RAS/MAPK pathway with a pipeline of small molecule inhibitors.
  • Novartis AG: A global pharmaceutical company with a strong oncology portfolio, including targeted therapies.

Erasca differentiates itself through its comprehensive approach to targeting oncogenic drivers and its commitment to combination therapies.

Risk Factors

Erasca faces several risks that could impact its business operations and financial performance:

  • Clinical and Regulatory Risks: The success of Erasca’s therapies depends on positive clinical trial results and regulatory approvals. Delays or failures in these areas could hinder the company’s progress.
  • Market Dependence: Erasca’s revenue potential is tied to the successful commercialization of its therapies. Market acceptance and competition could affect sales.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for its clinical and commercial operations. Disruptions in the supply chain could impact production timelines.
  • Financial Risks: As a clinical-stage company, Erasca incurs significant R&D expenses and may require additional funding to sustain its operations.

Recent Developments

Erasca has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trial Updates: The company recently announced positive interim results from its Phase 1/2 clinical trials for ERAS-007 and ERAS-601, demonstrating promising safety and efficacy profiles.
  • Partnerships: Erasca entered into a collaboration with a leading academic institution to explore novel targets in the RAS/MAPK pathway.
  • Corporate Milestones: The company successfully completed a public offering to raise additional capital for its R&D programs.
  • Global Developments: The COVID-19 pandemic posed challenges to clinical trial enrollment and supply chain operations, but Erasca implemented measures to mitigate these impacts.

Investment Considerations

Investors considering Erasca should weigh the following strengths and risks:

Strengths

  • Strong leadership team with extensive oncology expertise.
  • Robust pipeline targeting high-value oncogenic drivers.
  • Strategic partnerships and collaborations.
  • Commitment to innovation and precision oncology.

Risks

  • Clinical and regulatory uncertainties.
  • High R&D expenses and potential funding needs.
  • Competitive pressures from other biotech and pharmaceutical companies.
  • Dependence on successful commercialization of therapies.

Conclusion

Erasca, Inc. is a promising player in the biotechnology sector, with a clear mission to eradicate cancer through innovative therapies. The company’s focus on targeting oncogenic drivers, combined with its strong leadership and strategic partnerships, positions it for long-term success. While Erasca faces challenges typical of clinical-stage biotech companies, its robust pipeline and commitment to precision oncology provide a solid foundation for future growth. Investors should carefully consider the company’s strengths and risks as it continues to advance its mission of erasing cancer.